Company
Lonza Group Ltd
Headquarters: Basel, Switzerland
Employees: 16,218
Market Cap
CHF37.73 Billion
CHF as of Jan. 1, 2025
US$41.66 Billion
Lonza Group Ltd Categories
Switzerland Healthcare Diagnostics & ResearchSwitzerland Healthcare Switzerland Diagnostics & Research
Top Competitors by Market Capitalization
Industry: Diagnostics & Research
| Company | Market Cap (USD) |
|---|---|
| Thermo Fisher Scientific | $219.88 B |
| Danaher | $177.43 B |
| Siemens Healthineers AG | $59.19 B |
| Agilent Technologies, Inc. | $43.57 B |
| IQVIA Holdings Inc. | $37.39 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.
Top 1-year algo backtest: +327.04%
$10,000 in March 2024 would now be $42,704 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Financials
| Last Financial Reports Date | June 30, 2017 |
| Revenue TTM | CHF6.70 B |
| EBITDA | CHF1.50 B |
| Gross Profit TTM | CHF1.95 B |
| Profit Margin | 8.56% |
| Operating Margin | 18.02% |
| Quarterly Revenue Growth | -0.70% |
Stocks & Indices
Lonza Group Ltd has the following listings and related stock indices.
Stock: SIX: LONN wb_incandescent